Dagogo-Jack I, Abbattista A, Murphy JF, Krulewicz S, et al. Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies. J Thorac Oncol 2023;18:67-78.
PMID: 36184067